• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Fanapt Falls Flat! Link from the Street.com

Quote












Anonymous said:
Can't think of a drug , in any therapeutic catgegory, that was 8th or 9th in its class that was successful at all. There are examples of 3rd, 4th, or 5th drugs to class being successful but I think in all cases they were "better mousetraps" in some form or another. More convenient dosing, greater potency, better side effect profile, etc. Plus you can't "buy" the business anymore with gimmicks like NCN ( Novartis Consultant Network) trips with families to nice resorts etc. Why would a doc prescribe a drug with complicated bid dosing, heightened hopotensive warnings and if you actually dig into the studies, less efficacy than risperidone in schizophrenia. Oh, and have had to report a number of patients with weight gain.
Click to expand...

Fanapt still sinking, and fast!
 








There was a lot of Hell that went on with NVS and Fanapt. A lot of evil DMs! Beware of David E, I heard he's still with the company. I am glad I have moved on fr that co, and benefitted fr the class action lawsuit! Thanks for the extra $$$$$! Adieu!
 








Focalin XR is about to go generic! Focalin XR is the only product sustaining the Neuro-Psych division!

Fanapt sales are about $70 million at best. You can't keep 200 reps and managers for a $70 million dollar drug!

I hope you are making your future plans now!
 




Big announcement to come that Fanapt is going to have a life cycle management change. Going for new indications, bipolar, refractory depression, mental retardation with new formulation to extend patent life. Just like they did with Exelon. Problem is Dr Vassela likes to make some money back before investing more and just now realized they wont make a dime more with just schizophrenia indication. So he has to open the pocket book and invest in the drug. More news to follow
 




Anonymous said:
Big announcement to come that Fanapt is going to have a life cycle management change. Going for new indications, bipolar, refractory depression, mental retardation with new formulation to extend patent life. Just like they did with Exelon. Problem is Dr Vassela likes to make some money back before investing more and just now realized they wont make a dime more with just schizophrenia indication. So he has to open the pocket book and invest in the drug. More news to follow
Click to expand...

Nice try! new indications doesn't extend patent life. Studies for Bipolar and depression take way too long to complete and then file to get approved. Patent runs out in Nov of 2016. Must sell schiz indication for rest of life cycle.
 




Anonymous said:
Big announcement to come that Fanapt is going to have a life cycle management change. Going for new indications, bipolar, refractory depression, mental retardation with new formulation to extend patent life. Just like they did with Exelon. Problem is Dr Vassela likes to make some money back before investing more and just now realized they wont make a dime more with just schizophrenia indication. So he has to open the pocket book and invest in the drug. More news to follow
Click to expand...

You are ignorant.
 




....and you do know how to read. I said there would be a new formulation. The new indications would be developed using the new formulation so they would be under new patent protection. I knew that sales people would not be smart enough to figure it out so I even gave an example EXELON. Exelon is off patent but is making tons since the new formulation (read PATCH) is protected. Now who is the ignorant one. Moron
 




Anonymous said:
....and you do know how to read. I said there would be a new formulation. The new indications would be developed using the new formulation so they would be under new patent protection. I knew that sales people would not be smart enough to figure it out so I even gave an example EXELON. Exelon is off patent but is making tons since the new formulation (read PATCH) is protected. Now who is the ignorant one. Moron
Click to expand...

Yes there is an injectable being studied, but there is no other "formulation" you idiot!!
 




Anonymous said:
....and you do know how to read. I said there would be a new formulation. The new indications would be developed using the new formulation so they would be under new patent protection. I knew that sales people would not be smart enough to figure it out so I even gave an example EXELON. Exelon is off patent but is making tons since the new formulation (read PATCH) is protected. Now who is the ignorant one. Moron
Click to expand...

Exelon Patch is making "tons"? Where are you getting your information? Joke quote of the month!
 
























You see, this is where the rubber meets the road. They tell us we are committed to this franchise, but with no injectable in the pipeline now there is no way they keep neuropsych the way it is structured in place. They already have 2 or more gen med reps selling patch in a smaller territory than where we sell fanapt. The writing is on the wall, fragile x is not saving the salesforce, maybe 5 to 10 reps at max. There will be a consolidation of gen meds with us next year and will affect many more jobs no doubt. If you aren't lookikng your are toast!!
 




Top Bottom
Back
Quote